PhRMA Urges FDA To Flesh Out Medicare Act Provisions On 180-Day Exclusivity
A trade group representing drug originators has urged the U.S. Food and Drug Administration to define key terms in the Medicare Prescription Drug Act's patent reforms concerning 180-day marketing exclusivity....To view the full article, register now.
Already a subscriber? Click here to view full article